{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T10:32:49Z","timestamp":1792146769369,"version":"4.4.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jaci.2020.07.025","type":"journal-article","created":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T02:51:23Z","timestamp":1596682283000},"page":"940-948","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":208,"title":["Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies"],"prefix":"10.1016","volume":"146","author":[{"given":"Craig W.","family":"Freyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Porter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2020.07.025_bib1","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/sj.bmt.1705898","article-title":"Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation","volume":"41","author":"Loren","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaci.2020.07.025_bib2","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1038\/nrc.2016.97","article-title":"Engineered T cells: the promise and challenges\u00a0of cancer immunotherapy","volume":"16","author":"Fesnak","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jaci.2020.07.025_bib3","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jaci.2020.07.025_bib4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.blre.2015.10.003","article-title":"Chimeric antigen receptor T cell therapy: 25 years in the making","volume":"30","author":"Gill","year":"2016","journal-title":"Blood Rev"},{"key":"10.1016\/j.jaci.2020.07.025_bib5","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbmt.2016.09.002","article-title":"Chimeric antigen receptor T cells and hematopoietic cell transplantation: how not to put the CART before the horse","volume":"23","author":"Kenderian","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaci.2020.07.025_bib6","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/ajh.24238","article-title":"CAR T-cells merge into the fast lane of cancer care","volume":"91","author":"Frey","year":"2016","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jaci.2020.07.025_bib7","first-page":"1714","article-title":"Maintenance rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIB MAXIMA study","volume":"93","author":"Witzens-Harig","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jaci.2020.07.025_bib8","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/bcj.2014.64","article-title":"Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia","volume":"4","author":"Zugmaier","year":"2014","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.jaci.2020.07.025_bib9","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","article-title":"Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the Children\u2019s Oncology Group","volume":"30","author":"Hunger","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaci.2020.07.025_bib10","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children\u2019s Oncology Group Study","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.jaci.2020.07.025_bib11","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2020.07.025_bib12","series-title":"Kymriah [prescribing information]","year":"2019"},{"key":"10.1016\/j.jaci.2020.07.025_bib13","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jaci.2020.07.025_bib14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jaci.2020.07.025_bib15","series-title":"Yescarta [prescribing information]","year":"2019"},{"key":"10.1016\/j.jaci.2020.07.025_bib16","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory Large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jaci.2020.07.025_bib17","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1182\/blood-2014-05-552729","article-title":"Current concepts in the diagnosis and management of cytokine release syndrome","volume":"124","author":"Lee","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2020.07.025_bib18","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine release syndrome with chimeric antigen receptor T cell therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaci.2020.07.025_bib19","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/bjh.15644","article-title":"Cytokine release syndrome and neurotoxicity after CD19 chimeric antigen receptor-modified T cell therapy","volume":"183","author":"Hay","year":"2018","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jaci.2020.07.025_bib20","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1007\/s00277-019-03685-z","article-title":"Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy","volume":"98","author":"Jiang","year":"2019","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jaci.2020.07.025_bib21","first-page":"1276","article-title":"Management of coagulopathy associated with CTL019 CAR T-cell therapy","volume":"130","author":"Buechner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2020.07.025_bib22","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jaci.2020.07.025_bib23","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"key":"10.1016\/j.jaci.2020.07.025_bib24","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jaci.2020.07.025_bib25","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2020.07.025_bib26","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jaci.2020.07.025_bib27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2020.07.025_bib28","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/cid\/ciy152","article-title":"Cytokine release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with chimeric antigen receptor T cells","volume":"67","author":"Park","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jaci.2020.07.025_bib29","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1200\/JCO.19.01892","article-title":"Optimizing chimeric antigen receptor T-cell therapy for adults with acute lymphoblastic leukemia","volume":"38","author":"Frey","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jaci.2020.07.025_bib30","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jcyt.2017.04.001","article-title":"Monocyte lineage-derived IL-6 does not affect chimeric antigen receptor T-cell function","volume":"19","author":"Singh","year":"2017","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jaci.2020.07.025_bib31","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2020.07.025_bib32","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.jaci.2020.07.025_bib33","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.1016\/j.bbmt.2019.12.227","article-title":"Improved anti-tumor response of chimeric antigen receptor T cell (CART) therapy after GM-CSF inhibition is mechanistically supported by a novel direct interaction of GM-CSF with activated Carts","volume":"26","author":"Cox","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaci.2020.07.025_bib34","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ana.25315","article-title":"Neurotoxicity after CTL019 in a pediatric and young adult cohort","volume":"84","author":"Gofshteyn","year":"2018","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jaci.2020.07.025_bib35","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jaci.2020.07.025_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.jaci.2020.07.025_bib37","doi-asserted-by":"crossref","first-page":"224ra25","DOI":"10.1126\/scitranslmed.3008226","article-title":"Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia","volume":"6","author":"Davila","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2020.07.025_bib38","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jaci.2020.07.025_bib39","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jaci.2020.07.025_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2020.07.025_bib42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/s13045-018-0571-y","article-title":"Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel","volume":"11","author":"Porter","year":"2018","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jaci.2020.07.025_bib43","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaci.2020.07.025_bib44","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"New Engl J Med"},{"key":"10.1016\/j.jaci.2020.07.025_bib45","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD 19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaci.2020.07.025_bib46","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","article-title":"Preliminary results of prophylactic tocilizumab after axicabtagene ciloleucel (axi-cel; KTE-C19) treatment for patients with refractory, aggressive, non-Hodgkin lymphoma (NHL)","volume":"130","author":"Locke","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2020.07.025_bib47","doi-asserted-by":"crossref","first-page":"S275","DOI":"10.1016\/j.bbmt.2019.12.447","article-title":"Prophylactic tocilizumab in patients with relapsed refractory lymphoma treated with anti CD19 chimeric antigen receptor T cell therapy","volume":"26","author":"Ahmed","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaci.2020.07.025_bib48","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/j.bbmt.2019.12.105","article-title":"Risk-adapted tocilizumab decreases severe cytokine release syndrome (CRS) after CTL019 CD19-targeted chimeric antigen receptor (CAR) T-cell therapy for pediatric B-cell acute lymphoblastic leukemia (B-ALL)","volume":"26","author":"Myers","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaci.2020.07.025_bib49","doi-asserted-by":"crossref","first-page":"S269","DOI":"10.1016\/j.bbmt.2019.12.436","article-title":"Trial in progress: a phase 2, single-arm, open-label study of itacitinib (ITA) for the prevention of chimeric antigen receptor (CAR) T-cell-induced cytokine release syndrome (CRS)","volume":"26","author":"Park","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaci.2020.07.025_bib50","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2020.07.025_bib51","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2013 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jaci.2020.07.025_bib52","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/nrclinonc.2018.19","article-title":"Toxicity management after chimeric antigen receptor T cell therapy: one size does not fit \u2018ALL\u2019","volume":"15","author":"Teachey","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jaci.2020.07.025_bib54","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.jaci.2020.07.025_bib55","series-title":"Actemra [prescribing information]","year":"2019"},{"key":"10.1016\/j.jaci.2020.07.025_bib56","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1182\/blood.2019001463","article-title":"Preemptive mitigation of CD19 CAR T-cell cytokine release syndrome without attenuation of antileukemic efficacy","volume":"134","author":"Gardner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2020.07.025_bib57","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1182\/blood-2019-123051","article-title":"Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia","volume":"134","author":"Liu","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2020.07.025_bib58","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.bbmt.2019.12.603","article-title":"Earlier steroid use with axicabtagene ciloleucel (axi-cel) in patients with relapsed\/refractory large B cell lymphoma (R\/R LBCL)","volume":"26","author":"Topp","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaci.2020.07.025_bib59","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1126\/scitranslmed.aau5907","article-title":"The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on\/off switch for CAR T cells","volume":"11","author":"Mestermann","year":"2019","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaci.2020.07.025_bib60","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/bloodadvances.2018028720","article-title":"Pharmacologic control of CAR-T function using dasatinib","volume":"3","author":"Weber","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jaci.2020.07.025_bib61","doi-asserted-by":"crossref","first-page":"e630","DOI":"10.1016\/S2352-3026(19)30156-5","article-title":"Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open label, single-centre, pilot trial","volume":"6","author":"Ahmed","year":"2019","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jaci.2020.07.025_bib62","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity\u00a0after\u00a0adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jaci.2020.07.025_bib63","first-page":"P217","article-title":"Clinical outcomes for the phase 2, single-arm, multicenter trial of JCAR015 in adult B-ALL (ROCKET Study)","volume":"5","author":"DeAngelo","year":"2017","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.jaci.2020.07.025_bib64","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-reported neuropsychiatric outcomes of long-term survivors after chimer antigen receptor T cell therapy","volume":"26","author":"Ruark","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jaci.2020.07.025_bib65","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","article-title":"Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma","volume":"26","author":"Brudno","year":"2020","journal-title":"Nat Med"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009167492031099X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009167492031099X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:28:00Z","timestamp":1758792480000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009167492031099X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S009167492031099X"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2020.07.025","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2020.07.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 American Academy of Allergy, Asthma & Immunology","name":"copyright","label":"Copyright"}]}}